MACOMICS LTD
Company number SC612928 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
-£8,114,466
Balance sheet as at 2025-03-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2018-11-06
- Employees
- 23 (2025 accounts · was 19 in 2024)
- Registered office
- 137a George Street, Edinburgh, Scotland, EH2 4JY
- Postcode
- EH2 4JY
- Capital
- 3 GBP
- Accounts category
- Small
- Charges
- 0 outstanding
Accounts
- Last made up to
- 2025-03-31
- Next due by
- 2026-12-31
- Financial year end
- 31 March
Confirmation statement
- Last statement dated
- 2025-11-05
- Next due by
- 2026-11-19
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 5 current · 1 resigned
Group structure
Controlled by EPIDAREX CAPITAL III UK, LP — since 2020-02-27
From persons-with-significant-control filings on the public register.
Licensed visa sponsor
Licensed by the Home Office to sponsor worker visas: Skilled Worker (Worker (A rating)).
Matched by registered name to the register of licensed sponsors (Home Office, updated daily) — check the register itself before relying on it. Contains public sector information licensed under the Open Government Licence v3.0.
Contact details
- Website
- macomics.com
We develop precision medicines to modulate macrophages for the treatment of cancer, by bringing together world-leading cancer biologists.
Previous registered addresses 1
| Address | Changed on |
|---|---|
| 54 NORTHUMBERLAND STREET, EDINBURGH, EH3 6JE, UNITED KINGDOM | 2020-08-25 |
At this address
Among the biggest employers
of 35 similar companies in EH, with 23 staff.
Competitors Edinburgh
This company ranks 68 among research and experimental development on biotechnology in Edinburgh.
The class of 2018
36%
of the 439 companies in this sector incorporated in 2018 are still active today; 60% have since been dissolved.
A fact about the year, not a forecast for this company.